“We expect an outcome from the FDA next year and if that's positive, we expect global, widespread availability of this as a new option for men with metastatic castration-resistant prostate cancer,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.
“There really are many considerations regarding germline testing, results interpretation, implications for treatment or screening, and the familial hereditary implications of this whole field. Because of that, understanding the role of genetic counseling is critical, and also understanding the interplay with various somatic testing approaches is also really important,” says Veda N. Giri, MD.
“From our standpoint, bigger prostates bleed more…From that, we started taking a different approach for those larger prostates,” says Andrew Higgins, MD.
“We [at GenesisCare] would be really interested in looking at strategies to identify men that we think are aggressive but localized and offer them a chance to do a shorter course hormonal therapy, which is going to substantially improve quality of life without losing on the efficacy end,” says Bridget F. Koontz, MD.
“Both [IMPRESS trials] would suggest that if patients are motivated to see if they can continue to improve their curvature and avoid things like surgery—which for many patients…is a goal—continuing with the collagenase makes good sense,” says Matthew J. Ziegelmann, MD.
“Currently, there is no role for statins in management of LUTS,” says Jordan J. Kramer, MD.
“Always look at the patient as…a whole and not only [their] testosterone levels,” says Karim Sultan Haider, MD.
“What's most important [is] that…one dose does not just fit all,” says Martin M. Miner, MD.
“There's been a lot of evidence over the past few years that there's certainly a…correlation between dietary intake and risk of prostate cancer, [but] there's really not a whole lot of data on risk of development of lethal prostate cancer,” says Nima Sharifi, MD.
“There are a number of significant advantages of this new technology, including the maintenance of antegrade ejaculation, the short operative time [and] the exceptional outcomes postoperatively for the patient,” says Naeem Bhojani, MD, FRCSC.
“The RTOG-0815 study [of dose-escalated RT plus androgen suppression] has provided...data to have an intelligent conversation with our patients and provide them numbers so that they know what to expect,” says Bridget F. Koontz, MD.
"If you look at men who had sexual dysfunction at the beginning of the study, compared to men that had good sexual function at the beginning of a study, both groups of men have equal response to improvement in their lower urinary tract symptoms,” says Kevin T. McVary, MD, FACS.
A recap of presentations from AUA 2021 highlighting next steps using novel therapies as combination approaches to treat advanced prostate cancer.
Current limitations of real-world data available that support the use of novel therapies, including androgen receptor inhibitors, as treatment for advanced prostate cancer.
In response to a presentation from AUA 2021, Dr. Julie N. Graff considers the role of PSA kinetics as prognostic markers in advanced prostate cancer.
“The take-home message is that testicular cancer should definitely not be a taboo subject,” says Shawn Dason, MD.
“The idea that Aquablation [treats] any size and any shape of prostate really does seem to hold true for these cohorts of patients,” says Dean Elterman, MD, MSc, FRCSC.
“We were surprised to see that the majority of subjects in these simulations had testosterone levels within eugonadal range for all 3 dose's studies,” says Jay Newmark, MD, MBA.
“I would encourage other people to think about their own routines in the operating room, in the clinic, going to conferences, hosting conferences, doing interviews, and where each one of us could even slightly cut back,” says Stacy Loeb, MD, PhD, MSc.
“What our studies were looking at was a novel device that could potentially help bridge the gap between [endoscopic treatment and urethroplasty] to achieve endoscopic treatment and achieve greater success,” says Justin Chee, MD.
“Doing this study allows us to say, 'With repeat treatments, we're not seeing a greater risk of retention, and we're not seeing a greater risk of UTI,'" says David A. Ginsberg, MD.
An expert in endourology discusses concerns with currently available treatment options for enteric hyperoxaluria and comments on detecting the disease for patients with recurring stones.
“The goal of this study was to look at that original phase 3 trial data [from 2013] and see if we could identify how much change in curvature patients were achieving with each of those 2 injections,” says Matthew J. Ziegelmann, MD.
“Most importantly, for the safety [of the] study…it looks like the medication has no really concerning adverse effects,” says Ronald Swerdloff, MD.
“I think that a lot of the best practices that the surgeons had developed and honed were really excellent communication skills, and…building a trusting physician-patient relationship, where they truly provided an informed consent of all the risks, all the benefits, [and] all the alternatives,” says Una Lee, MD, FPMRS.
Based on long-term data and clinical experience treating advanced prostate cancer with androgen receptor inhibitors, Drs Julie N. Graff and Benjamin H. Lowentritt suggest ideas for future study.
Considerations that factor into which androgen receptor inhibitor is selected as treatment for nonmetastatic castration-resistant prostate cancer.
“Most importantly, the improvement that they were able to get during the first couple of years is sustained, whereas what we expect in untreated men [is that] their erectile function…keeps on deteriorating,” says Karim Sultan Haider, MD.
“[Attendees] will be learning multiple aspects in terms of the genetic evaluation for men with prostate cancer,” says Veda N. Giri, MD.
Welcome to another installment of Uranimals, a video series featuring urologists and their pets, brought to you by urology times. From a snuggling cat companion to an Australian parakeet, we have some more great guests for you!
